GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (STU:47N) » Definitions » Additional Paid-In Capital

Citius Pharmaceuticals (STU:47N) Additional Paid-In Capital : €256.48 Mil(As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals Additional Paid-In Capital?


Citius Pharmaceuticals's quarterly additional paid-in capital increased from Dec. 2023 (€234.79 Mil) to Mar. 2024 (€238.48 Mil) and increased from Mar. 2024 (€238.48 Mil) to Jun. 2024 (€256.48 Mil).

Citius Pharmaceuticals's annual additional paid-in capital increased from Sep. 2021 (€193.87 Mil) to Sep. 2022 (€234.69 Mil) and increased from Sep. 2022 (€234.69 Mil) to Sep. 2023 (€236.97 Mil).


Citius Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Citius Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Additional Paid-In Capital Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.79 88.47 193.87 234.69 236.97

Citius Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 230.59 236.97 234.79 238.48 256.48

Citius Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Citius Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Citius Pharmaceuticals Headlines

No Headlines